

# Subject Index

## A

Abuse of dominance, Article 102 TFEU  
  ambulance services, 232  
  AstraZeneca, 230  
  compulsory affiliation, 232  
  econometric models, 228  
  entry barriers, 229  
  exploitation and exclusion, 229  
  French legislation, 233  
  geographic market, 227  
  IMS Health, 230  
  insurance-based Bismarck systems, 228  
  market shares, 229  
  pharmaceutical company, 231  
  private entities, 233  
  product market, 227  
  product safety, 230  
  SGEI mission, 232  
  shortage of medicines, 231  
  SSNIP test, 228  
Alternative Dispute Resolution (ADR),  
  208  
Amsterdam Treaty, 210  
Appellate Body (AB) Report  
  Article 11 DSU, 285–286  
  continued suspension  
    *Australia–Apples*, 282  
    standard of review, 280–282  
  dispute settlement bodies, 278  
  IRA, 283

  materiality of flaws, 285  
  objective assessment of facts, 285–286  
  risk assessor, 283  
  scientific uncertainty, 283–285  
  SPS Agreement, 279  
  WTO Panels, 277  
Appropriate Level of Protection  
  (ALOP), 277  
*Australia–Measures Affecting the Importation  
  of Apples from New Zealand  
  (Australia–Apples)*,  
  WT/DS367/AB/R, adopted 29  
  Nov. 2010  
Article 11 DSU, 285–286  
continued suspension  
  Australia–Apples, 282  
  standard of review, 280–282  
dispute settlement bodies, 278  
IRA, 283  
materiality of flaws, 285  
objective assessment of facts,  
  285–286  
risk assessor, 283  
scientific uncertainty, 283–285  
SPS Agreement, 279  
WTO Panels, 277

## B

Berne Convention, 67  
Bilateral investment treaties (BITs), 119

Bioethics. *See Ethics, EU biomedical law*

Biomedicine and EU law. *See European*

*Union (EU) biomedical law*

Blood donation, 7

## C

CARIFORUM-EC Economic

Partnership Agreement

Article 19(2), 192

Cotonou Agreement, 189

future rights, 195–197

MFN provisions, 190, 191

negative criticism, 190

paragraph 2(c) of Enabling Clause,

192–195

*Carmen media*, Case C-46/08, 259

Cartel prohibition, health care

health care and Article 101 TFEU

collective supplementary pension

scheme, 225

consumer welfare, 224

*GlaxoSmithKline* case, 223

medical infrastructure and

equipment, 225

parallel trade, 224

*Pavlov* case, 225

price regulation, 224

legitimate objectives

anti-doping rules, 226

Dutch Bar Association, 226

medical deontology, 226

professional ethics, 226

sector-specific approach, 225

Cassis de Dijon doctrine, 35

CEBS. *See Committee of European Banking*

*Supervisors (CEBS)*

CEPA. *See Closer Economic Partnership*

*Agreement (CEPA)*

China, market manipulation

date of loss, 147, 148

legislative schemes, 147

loss causation, 150, 152

mitigation, 156–157

purchase causation, 150–151

remoteness, 154–156

systematic/extraneous losses, 153

CJEU. *See Court of Justice of the European*

*Union (CJEU)*

Cloning, 9, 11, 18

Closer Economic Partnership Agreement

(CEPA)

economic and trade exchanges, 322

legal profession, 322–323

liberalization negotiations, 323

liberalization of legal services

association, 329–332

economic development, 337

employing Mainland practicing

lawyers, 333–335

Mainland legal affairs, 332–333

national judicial examination,

335–336

policy makers, 336

requirement of actual need, 336

requirement of transparency,

328–329

residency requirement, 335

Mainland China

commercial presence, 324, 325

consumption abroad, 324

cross-border supply, 324

economic and trade relations, 326

Foreign investments and trade,

323

foreign law firms, 337

GATS, 325

Joint Steering Committee, 327

market access and national

treatment, 324

national treatment principle, 325

non-litigation areas, 338

residency requirement, 326

WTO commitments, 325

WTO agreements, 321–322

Committee of European Banking

Supervisors (CEBS), 36

- Committee of European Insurance and Occupational Pensions Supervisors (CEIOPS), 36
- Committee of European Securities Regulators (CESR), 36
- Competition and international economic law, competitive relationships
  - demand substitutability
    - assessment of comparability, investment protection, 124–125
    - assessment of similar products in EU law, 124
    - Border Tax Adjustments* framework, 122–124
    - economic approach, 125–129
    - relevant market analysis, 120–122
  - free market economy, 116–117
  - market distortions, 116
  - market power and market definition, 117–118
  - non-discrimination and comparator clauses, 118–119
  - supply substitutability
    - international trade in goods, 132–134
    - international trade in services, 134–135
    - investment protection, 135–136
    - market power and market definition, 130–131
    - non-discrimination obligations, 131–132
    - potential and future competition, 136–137
    - relevant product market, 130–131
- Consumer Protection Cooperation Regulation, 208
- Copyright theory, 81–82
- Cotonou Agreement, 189
- Court of Justice of the European Union (CJEU)
  - Carmen Media*, Case C-46/08, 253
  - carte blanche* case law
    - channeling argument, 247
    - consumer protection, 248
    - fraud and incitement, prevention of, 248
    - free movement rules, 246
    - Läärrä judgment, 246
    - principle of consistency, 247
    - Schindler*, 245
    - slot machine gambling, 246
    - Zenatti* judgment, 247
  - Engelmann*, Case C-64/08, 253–254
  - EU law, 260–261
  - German courts, 252
  - internet gambling case law
    - gambling services, 250
    - Ladbrokes* and *Betfair* judgments, 251
    - Liga Portuguesa*, 250
    - national gaming licenses, 252
    - obligation of transparency, 251
  - Länder*, 253
  - limited competition, 259–260
  - Member States, 252–254
  - nuanced approach case law
    - betting and gaming sector, 250
    - business practice, 248
    - criminal/fraudulent activities, 250
    - Gambelli* judgment, 248
    - hybrid policy, 249
    - licensing system, 250
    - Lindman*, 249
    - monopoly system, 249
    - Placanica* case, 249
    - principle of mutual recognition, 249
  - overriding public interests, 254
  - principle of consistency, 257–259
  - Stoss and Others*, Case C-316/07, C-358/07 to C-360/07, C-409/07, and C-410/07, 253
  - system of protection, 255–257
  - Winner Wetten*, Case C-409/06, 253
- Customs valuation agreement (CVA), 351

**D**

de Larosiere Report (DLR), 37–38

**E**

ECN. *See Electronic Communications Network (ECN)*

Economic and Financial Affairs  
(ECOFIN) Council, 33

Economic and monetary union (EMU),  
107

EFSM. *See European Financial Stability  
Mechanism (EFSM)*

EGE. *See European Group of Ethics (EGE)*

Electronic Communications Network  
(ECN), 234

Embryonic research, 9

*Engelmann*, Case C-64/08, 253–254,  
259–260

ENISA. *See European Network and  
Information Security Agency (ENISA)*

ESFS. *See European System of Financial  
Supervisors (ESFS)*

ESRB. *See European Systemic Risk Board  
(ESRB)*

Ethics, EU biomedical law

bioethics committees, 14

Blood directive, 16

Clinical Trials directive, 16

Community legislation, 15

democratic governance, 24–28

direct incorporation

Clinical Trials directive, 18–19

European Group of Ethics, 19–21

Patents directive, 17–18

research policy, 19

Tissue directive, 18

externalizing political conflict, 21–22

lawmaking process, 14–16

new modes of governance, 22–23

Patents directive, 15–16

policy conflicts, 17

secular moral reasoning, 14

Tissue directive, 16

EU Competition Law and health care

anticompetitive agreements, 215

effet utile, direct effect, 236–238

free movement law, 213

guidance, 235

harmonization legislation, 213

Member States, 214

national application, 215

National Rules, 234

NCAs, 214

spontaneous harmonization, 214

undertaking

economic activity, 216

evaluation, 222–223

health-care providers, 216–218

national bodies, health-care schemes,  
218–221

national qualifications, 215

Euro crisis

economic and monetary union,  
107–110

energy and environmental crises, 114

global power shifts, 113–114

Greek refugee crisis, 114

institutional developments, 110–111

International Monetary Fund,  
111–113

poverty, 114

European and Community Patent Court  
(ECPC), 301

European Banking Authority (EBA), 34,  
40

European Competition Network, 211

European Competition Network (ECN).  
*See European System of Financial  
Supervisors (ESFS)*

European Consumer Protection  
Enforcement Network, 211

European Economic Community Treaty,  
69

European Financial Stability Facility  
(EFSF), 110–111

European Financial Stability Mechanism

- (EFSM), 110–111
- European Group of Ethics (EGE), 19–21
- European Insurance and Occupational Pensions Authority (EIOPA), 40
- European Network and Information Security Agency (ENISA), 42–45
- European Patent Convention (EPC), 298
- European Securities and Market Authority (ESMA), 40
- European Stability Mechanism (ESM), 111
- European Supervisory Authorities (ESAs).  
     *See European System of Financial Supervisors (ESFS)*
- European Systemic Risk Board (ESRB), 33
- European System of Financial Supervisors (ESFS)
  - Cassis de Dijon doctrine, 35
  - commission proposal, 38–39
  - decentralized approach, 37
  - de Larosiere Report and commission proposal, 37–38
  - vs.* European Competition Network
    - application of EU law, 55–57
    - case allocation, 55
    - cooperation and information exchange, 54
    - delegation, 55
    - EU interventions, 57–58
    - rationale of comparison, 52–53
    - structure, 53–54
- European Parliament, 39–40
- European Supervisory Authorities
  - Article 95 EC, 41–42
  - Article 308 EC, 45
  - binding individual decisions, 48–49
  - Board of Supervisors, 39
  - challenges, 34
  - dispute settlement competences, 39
  - ENISA, 42–45
  - Meroni doctrine, 49–52
  - new triplet of agencies, 40–41
  - non-binding decision-making powers, 48
  - powers of commission, 46–47
  - regulatory agencies, 49
  - Treaty amendment, 46
- Lamfalussy approach
  - level 3 committees, 36–37
  - structure, 35–36
- national financial regulators and supervisors, 35
- European Union (EU) biomedical law
  - ethics
    - bioethics committees, 14
    - Blood directive, 16
    - Clinical Trials directive, 16
    - Community legislation, 15
    - democratic governance, 24–28
    - direct incorporation, 17–21
    - externalizing political conflict, 21–22
    - lawmaking process, 14–16
    - new modes of governance, 22–23
    - Patents directive, 15–16
    - policy conflicts, 17
    - secular moral reasoning, 14
    - Tissue directive, 16
  - fundamental and societal issues, 5
  - parallel evolution
    - body of law, 9–13
    - internal market legislation, 6
    - non-market values, 6–7
    - tissue economy, 7–9
- European Union (EU) citizenship
  - Advocate General Sharpston opinion
    - fundamental rights, 266–268
    - reverse discrimination, 265–266
    - self-standing right of residence, 265
  - Article 20 TFEU and directive 2004/38
    - cross-border situations, 271
    - free movement rights, 271
    - Grzelczyk* and *Baumbast* cases, 269
    - principle of proportionality, 270
    - Rottmann* case, 270

- secondary Community law, 269
- Court of Justice judgment, 268
- facts, 265
- Flemish care insurance* case, 263
- purely internal rule
  - economic freedoms, 273
  - free movement law, 271
  - market citizenship, 272
  - Treaty of Lisbon, 273
  - Treaty of Maastricht, 272
- residence rights, 264
- reverse discrimination, 274–275

## F

- Financial Services and Markets Act, 146
- Flemish care insurance* case, 263, 265
- Food and non-alcoholic beverages
  - artificial separation, 398–399
  - objective justification
    - necessity, 401
    - suitability, 399–401
- Free trade agreement (FTA), 341
- Free trade theory
  - availability of variety, 79
  - post-sale support, 79–80
  - price, 80
  - quality of goods, 78–79

## G

- Gambling
  - CJEU case law
    - carte blanche case law, 245–248
    - EU law, 260–261
    - internet gambling case law, 250–252
    - limited competition, 259–260
    - Member States, 252–254
    - nuanced approach case law, 248–250
    - overriding public interests, 254
    - principle of consistency, 257–259
    - system of protection, 255–257
  - German policy rules, 245
  - licensing-based system, 244
  - Member States, 244

- national courts, 261
- national governments, 243
- national licensing system, 244
- General Agreement on Trade in Services (GATS), 118, 119
- Gene technology, 9

## H

- Harmonization
  - ADR schemes, 208
  - collective redress, 207
  - consumer law and competition law, 208
  - EU legislation, 207
  - European Commission, 207
  - Green Paper, 208
  - internal market, 210
  - international IPR exhaustion debate
    - contractual approach and competition laws, 75–76
    - self-help, 75
  - learning process, 211
  - National laboratories, 211
  - national procedural rules, 209
  - principle of subsidiarity, 210
  - private law rules and civil procedures, 210
  - Staff Working Paper, 209
  - White Paper's proposals, 208
- Harmonized Commodity Description and Coding System, 77

## I

- IIPs. *See Information-intensive products (IIPs)*
- Import Risk Analysis (IRA), 282
- Information-intensive products (IIPs), 65–66, 73–74
- Intellectual property rights (IPRs)
  - exhaustion debate
    - current international debate
      - Berne Convention, 67
      - EU's community exhaustion, 68–69
      - national exhaustion jurisdictions, 68
      - Paris Convention, 67

- regional exhaustion, 68–69
- TRIPs Agreement, 67–68
- first-sale doctrines, 65–66
- harmonization
  - contractual approach and
    - competition laws, 75–76
  - self-help, 75
- information-intensive products, 65–66, 73–74
- overlapping and competing interests, 70–73
- product class-based approach
  - free trade theory, 78–81
  - Harmonized Commodity
    - Description and Coding System, 77
  - national interests, 83–85
  - patent and copyright theory, 81–82
  - trademark theory, 82–83
  - WTO policy perspective, 85
- International Monetary Fund (IMF), 111–113

**J**

- Japan-Association of Southeast Asian Nations (ASEAN) agreements
  - Japan-Indonesia EPA (JIEPA), 367–370
  - Japan-Malaysia EPA (JMEPA), 363–366
  - Japan-Philippines EPA (JPEPA), 370–374
  - Japan-Singapore EPA (JSEPA), 374–375
  - Japan-Thailand EPA (JTEPA), 375–378
  - Japan-Vietnam EPA (JVEPA), 378–380

**L**

- Lisbon Treaty, 1–4

**M**

- Market manipulation
  - Chinese law
    - date of loss, 147, 148
    - legislative schemes, 147

- loss causation, 150, 152
- mitigation, 156–157
- purchase causation, 150–151
- remoteness, 154–156
- systematic/extraneous losses, 153
- false statement, 145–146
- UK law
  - date of loss, 148
  - extraneous losses, 153
  - legislative schemes, 146–147
  - loss causation, 150
  - mitigation, 157
  - presumptive causation approach, 149
  - remoteness, 155

**US law**

- date of loss, 147–148
- extraneous losses, 149, 153
- legislative schemes, 146
- mitigation, 156
- purchase causation, 149
- remoteness, 154–155

- Members of the European Parliament (MEPs), 2–3

- Meroni doctrine, 49–52

- Monopoly systems, 256

- Munich Convention, 298

**N**

- National Competition Authorities (NCAs), 214

- New modes of governance (NMGs), 22–23

- Nice Treaty, 2

- North American Free Trade Association (NAFTA), 119

**O**

- Opinion 1/09, European Court of Justice
  - admissibility of request, 302–303
  - draft agreement
    - commission's communication of 2007, 298–299
  - judiciary *volet*, 301–302

- two-pillar approach, 299–301
- dualism, 320
- ECHR
  - infringement procedure, 311
  - Luxembourg Court, 313
  - preliminary ruling jurisdiction, 310
  - principle of structure, 312–313
  - principle of subsidiarity, 312
  - prior involvement mechanism, 313
- EU patent litigation system
  - Benelux Court archetype, 315–318
  - Community trademark courts, 314
  - unified patent litigation system, 318–319
- national tribunal notion, 320
- substance
  - direct cooperation, 306
  - new legal order, 303–304
  - preliminary ruling mechanism, 305–306
  - principle of non-contractual liability, 306
  - principle of sincere cooperation, 304
- Union judicial system, 307–310

## P

Paris Convention, 67

Patent

- directive, 15–16
- human living material, 15
- intellectual property, 81–82

Preferential trade agreements (PTAs),

WTO

- Co-existence-to-Coherence concept, 293

- discrimination, 294

- dispute settlement systems, 293

- Doha negotiations, 294

- GATS commitments, 292

- most-favoured nation, 293

- multilateral trading system, 295

- NAFTA, 291

- non-binding provision, 293

- soft-law approach, 295

- Uruguay Round commitments, 292

Product class-based approach,

- international IPR exhaustion debate

- free trade theory

- availability of variety, 79

- post-sale support, 79–80

- price, 80

- quality of goods, 78–79

- Harmonized Commodity Description and Coding System, 77

IP theory

- patent and copyright protection, 81–82

- trademark protection, 82–83

national interests

- development, 84–85

- public health interests, 83

WTO policy perspective, 85

## R

Reproductive rights, 8

## S

Sanitary and Phytosanitary (SPS)

- Agreement, 278

Securities Exchange Act of 1934, 146

Securities fraud compensation

Chinese law

- date of loss, 147, 148

- legislative schemes, 147

- loss causation, 150, 152

- mitigation, 156–157

- purchase causation, 150–151

- remoteness, 154–156

- systematic/extraneous losses, 153

- market manipulation by false statement, 145–146

UK law

- date of loss, 148

- extraneous losses, 153

- legislative schemes, 146–147

- loss causation, 150



mitigation, 157  
 presumptive causation approach, 149  
 remoteness, 155  
 US law  
   date of loss, 147–148  
   extraneous losses, 149, 153  
   legislative schemes, 146  
   mitigation, 156  
   purchase causation, 149  
   remoteness, 154–155  
 Sherman Antitrust Act, 117  
 Small but Significant Non-transitory  
   Increase in Price (SSNIP), 227  
 Soft drugs  
   Advocate General Bot opinion  
     cannabis, 391  
     coffee shops, 392  
     fundamental freedoms, 392  
     hemp-based drugs, 391  
     narcotic product, 391  
     principle of freedom, 390  
 Dutch policy of tolerance, 395–396  
 ECJ judgment  
   EU free movement provisions, 393  
   Member States, 393  
   necessity criterion, 394  
   non-alcoholic beverages and food,  
     393  
   suitability criterion, 394  
 food and non-alcoholic beverages  
   artificial separation, 398–399  
   objective justification, 399  
 free movement of drugs, 397–398  
*Happy Family* judgment, 396  
 national court  
   AHOJG criteria, 389  
   municipality of Maastricht, 390  
   policy of tolerance, 389  
   residence condition, 390  
 prosecution capacity, 396  
 Spanish National Health System (SNS),  
   220  
 Stability and Growth Pact, 1

Stability and Growth Pact (SGP), 108  
 Supply substitutability, competitive  
   relationships  
     competition law, 130–131  
   international economic law  
     international trade in goods,  
       132–134  
     international trade in services,  
       134–135  
     investment protection, 135–136  
     non-discrimination obligations,  
       131–132  
     potential and future competition,  
       136–137  
   potential and future competition,  
     136–137  
 Surrogate motherhood, 8

## T

Technical assistance (TA) obligations  
   customs valuation agreement, 351  
   developing country policymakers, 342  
 DSU, 355–356  
 FTA, 341  
 GATS, 352–354  
 government procurement, 357–358  
 Japan-ASEAN EPAs  
   Japan-Indonesia EPA (JIEPA),  
     367–370  
   Japan-Malaysia EPA (JMEPA),  
     363–366  
   Japan-Philippines EPA (JPEPA),  
     370–374  
   Japan-Singapore EPA (JSEPA),  
     374–375  
   Japan-Thailand EPA (JTEPA),  
     375–378  
   Japan-Vietnam EPA (JVEPA),  
     378–380  
 pre-shipment inspection, 352  
 regionalism-multilateralism debate,  
   384–386  
 SPS Agreement, 350–351

- TBT Agreement, 348–349
  - TPR mechanism, 356–357
  - TRIPS Agreement, 354–355
  - WTO agreements
    - Doha Round, 359
    - safeguards, 358
    - subsidies and countervailing measures, 358
    - trade facilitation/customs procedures, 359
    - TRIMs, 358
  - WTO-plus elements
    - agreement on development facilitation, 343
    - bilateral schemes, 348
    - binding obligations, 343, 345
    - intellectual property protection, 346
    - mutually agreed terms and conditions, 343
    - preferential tariff, 344
  - Technical barrier to trade (TBT), 348–349
  - Tissue economy
    - bioethics, 8
    - blood donation, 7
    - cloning, 9, 11
    - competition state, 11
    - dignitarian alliance, 9
    - globalization, 11
    - legal regulation, 11–13
    - stem cells, 7–8
    - surrogate motherhood, 8
    - tissue circulation, 7
  - TNT Express Nederland BV v. AXA Versicherung AG*, Case No. C-533/08
  - Advocate General Kokott opinion, 95–96
  - comments
    - Article 31 of the CMR, 101–102
    - CoE Convention, 100–101
    - disconnection clause, 100
    - importance of amsterdamization, 98–99
    - Mutatis mutandis*, 101
    - specialized conventions, 97–98
  - Court's judgment
    - Article 71 of Regulation No 44/2001, 93–95
    - Article 31 of the CMR, 95
    - preliminary points, 92–93
  - facts, 90–92
  - Trademark theory, 82–83
  - Trade policy review (TPR), 356–357
  - Trade Policy Review Mechanism (TPRM), 179
  - Trade-Related Investment Measures (TRIMs), 358
  - TRIPs Agreement, 67–68
- U**
- Undertaking, EU competition law
    - economic activity, 216
    - evaluation
      - Beveridge system, 222
      - tax-based health-care systems, 223
    - health-care providers
      - Bismarck systems, 217
      - financial risks, 216
      - goods and services, 216
      - medical treatment, 217
    - national bodies, health-care schemes
      - AG2R Prévoyance*, 221
      - Dutch health insurance companies, 219
      - FENIN* logic, 220
      - German health insurance funds, 218
      - insurance premiums, 218
      - principle of solidarity, 218
      - public procurement law, 220
      - risk equalization system, 219
      - sickness funds, 219
      - state supervisory mechanisms, 221

national qualifications, 215  
 United Kingdom, market manipulation  
   date of loss, 148  
   extraneous losses, 153  
   legislative schemes, 146–147  
   loss causation, 150  
   mitigation, 157  
   presumptive causation approach, 149  
   remoteness, 155  
 United States, market manipulation  
   date of loss, 147–148  
   extraneous losses, 149, 153  
   legislative schemes, 146  
   mitigation, 156  
   purchase causation, 149  
   remoteness, 154–155

## V

*Vodafone Ltd, et al. v. Secretary of State for  
 Business, Enterprise and Regulatory  
 Reform*, Case No. C58/08  
 Article 114 TFEU, 199–202  
 concluding observations, 203–205  
 principle of proportionality, 202–203  
 principle of subsidiarity, 203

## W

*Winner Wetten*, Case C-409/06, 260–261  
 World Trade Organization (WTO)  
   access to information, 171–172  
   agreements  
     CVA, 351  
     Doha Round, 359  
     GATS, 352–354  
     Marrakesh Agreement, 355–356  
     pre-shipment inspection, 352  
     safeguards, 358  
     SPS, 350–351  
     subsidies and countervailing  
       measures, 358  
     TBT, 348–349  
     TPR, 356–357

trade facilitation/customs  
   procedures, 359  
   TRIMs, 358  
   TRIPS, 354–355  
 anti-democratic decision-making  
   mechanism, 165  
 domestic stakeholder participation  
   business sector participation,  
     180–181  
   domestic consultation, 178–180  
   two-level game concept, 178  
 First Warwick Commission, 164  
 NGO participation, 172–177  
 parliamentary participation,  
   168–171  
 preferential trade agreements  
   Co-existence-to-Coherence  
     concept, 293  
   discrimination, 294  
   dispute settlement systems, 293  
   Doha negotiations, 294  
   GATS commitments, 292  
   most-favoured nation, 293  
   multilateral trading system, 295  
   NAFTA, 291  
   non-binding provision, 293  
   soft-law approach, 295  
   Uruguay Round commitments,  
     292  
 rational and adequate perspective  
   Declaration on external  
     transparency, 181–182  
   domestic level, 183–184  
   limitations, 181  
   WTO level, 182–183  
 reform initiatives, 164  
 requirement of democratic  
   decision-making process  
     deliberation and rational discourse,  
       166–167  
     representation, 166  
 Sutherland Report, 164